Survival in Malignant Peripheral Nerve Sheath Tumours: A Comparison between Sporadic and Neurofibromatosis Type 1-Associated Tumours

Sarcoma · 2009 · Classic · cited 163 times

D. Porter, Vishal Prasad, L. Foster, Graham F. Dall, R. Birch, Robert John Grimer

Orthopaedic Oncology

SUMMARY — THE REDUCTIONIn 123 MPNST patients, 5-year survival was worse for NF1-associated than sporadic tumors (33% vs 63%); NF1 status and tumor volume independently predicted poor outcome, so NF1 should factor into staging.
Abstract, as published

We studied 123 patients with malignant peripheral nerve sheath tumours (MPNSTs) between 1979 and 2002. However, 90 occurred sporadically whereas 33 were associated with neurofibromatosis type 1 (NF1). Survival was calculated using Kaplan-Meier survival curves and we used Cox's proportional hazards model to identify independent prognostic factors. A 5-year survival for 110 nonmetastatic patients was 54%; (33% NF1 and 63% sporadic P = .015). Tumour stage and site were significant prognostic indicators after univariate analysis. After multivariate analysis, however, only NF1 (P = .007) and tumour volume more than 200 m (P = .015) remained independent predictors of poor outcome. We recommend that NF1 be taken into account during MPNST staging. As the survival rate in the NF group was dependant on tumour volume, routine screening of these patients with FDG PET and/or MRI may be warranted, thereby staging and controlling them at the earliest possible opportunity.

Featured in the 2026-11-06 issue.

← Beyond the dura: is more always better? A recovery-first reap…Role of vertebroplasty and balloon kyphoplasty in pathologica… →

The Reduction is a free email digest of newly published orthopaedic literature — a handful of new papers in the subspecialties you choose, each summarized like this one. Subscribe free or browse the archive.